Target Name: ERMARD
NCBI ID: G55780
Review Report on ERMARD Target / Biomarker Content of Review Report on ERMARD Target / Biomarker
ERMARD
Other Name(s): dJ266L20.3 | ERMARD variant 1 | C6orf70 | ER membrane-associated RNA degradation protein | PVNH6 | Endoplasmic reticulum membrane-associated RNA degradation protein | transmembrane protein C6orf70 | EMARD_HUMAN | ER membrane associated RNA degradation | Endoplasmic reticulum membrane-associated RNA degradation protein (isoform 1) | ER membrane associated RNA degradation, transcript variant 1

ERMARD: A Protein Regulator of Cell Signaling and Inflammation

ERMARD (dJ266L20.3) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the evolutionarily conserved superfamily of cytoplasmic determinants, which includes proteins that play important roles in various cellular processes, including cytoskeletal organization, cell adhesion, and signaling pathways.

One of the most significant functions of ERMARD is its role in cell signaling. It is a key regulator of the T-cell receptor (TCR), which is responsible for cell recognition and differentiation. In addition, ERMARD is involved in the regulation of cell proliferation and apoptosis, which are critical processes that maintain tissue homeostasis and ensure the integrity of the immune system.

ERMARD has also been shown to play a role in the regulation of inflammation. It is a potent inhibitor of the nuclear factor kappa B (NFKB), a transcription factor that is involved in the regulation of inflammation and inflammation-related processes. This suggests that ERMARD may be a potential therapeutic target for the treatment of inflammatory disorders.

In addition to its role in cell signaling and inflammation, ERMARD is also a potential drug target for several diseases. For example, it has been shown to be downregulated in various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. This suggests that targeting ERMARD may be a promising strategy for the development of new treatments for these diseases.

ERMARD is also a potential biomarker for several diseases. Its expression has been shown to be reduced in a variety of diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. This suggests that analyzing ERMARD levels may be a useful diagnostic tool for the diagnosis and monitoring of these diseases.

In conclusion, ERMARD is a protein that plays important roles in various cellular processes in the body. Its function as a regulator of cell signaling and inflammation makes it a potential therapeutic target for the treatment of a variety of diseases. In addition, its potential as a biomarker for the diagnosis and monitoring of disease makes it an important area of research for the study of these conditions. Further studies are needed to fully understand the role of ERMARD in these processes and its potential as a therapeutic target.

Protein Name: ER Membrane Associated RNA Degradation

Functions: May play a role in neuronal migration during embryonic development

The "ERMARD Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ERMARD comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

ERMN | ERMP1 | ERN1 | ERN2 | ERO1A | ERO1B | ERP27 | ERP29 | ERP44 | ERRFI1 | ERV3-1 | ERVFRD-1 | ERVK-6 | ERVK13-1 | ERVMER34-1 | ERVV-1 | ERVV-2 | ERVW-1 | ESAM | ESAM-AS1 | ESCO1 | ESCO2 | ESCRT-0 complex | ESCRT-I complex | ESCRT-II complex | ESCRT-III complex | ESD | ESF1 | ESM1 | ESPL1 | ESPN | ESPNL | ESPNP | ESR1 | ESR2 | ESRG | ESRP1 | ESRP2 | ESRRA | ESRRB | ESRRG | ESS2 | Estrogen receptor | Estrogen-related receptor (ERR) (nonspecifed subtype) | ESX1 | ESYT1 | ESYT2 | ESYT3 | ETAA1 | ETF1 | ETFA | ETFB | ETFBKMT | ETFDH | ETFRF1 | ETHE1 | ETNK1 | ETNK2 | ETNPPL | ETS1 | ETS2 | ETS2-AS1 | ETV1 | ETV2 | ETV3 | ETV3L | ETV4 | ETV5 | ETV6 | ETV7 | Eukaryotic translation initiation factor 2-alpha kinase | Eukaryotic translation initiation factor 2B | Eukaryotic translation initiation factor 3 (eIF-3) complex | Eukaryotic Translation Initiation Factor 4A (eIF-4A) | Eukaryotic Translation Initiation Factor 4E Binding Protein | EVA1A | EVA1A-AS | EVA1B | EVA1C | EVC | EVC2 | EVI2A | EVI2B | EVI5 | EVI5L | EVL | EVPL | EVPLL | EVX1 | EVX1-AS | EVX2 | EWSAT1 | EWSR1 | EXD1 | EXD2 | EXD3 | EXO1 | EXO5 | EXOC1 | EXOC1L